WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2003077927) SULFATASE INHIBITING PROGESTOGEN-ONLY CONTRACEPTIVE REGIMENS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2003/077927    International Application No.:    PCT/US2003/007451
Publication Date: 25.09.2003 International Filing Date: 11.03.2003
Chapter 2 Demand Filed:    09.10.2003    
IPC:
A61K 9/00 (2006.01), A61K 9/70 (2006.01), A61K 31/567 (2006.01)
Applicants: JANSSEN PHARMACEUTICA N.V. [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE) (For All Designated States Except US).
CAUBEL, Patrick, Michel [FR/US]; (US) (For US Only).
FRIEDMAN, Andrew, Joseph [US/US]; (US) (For US Only)
Inventors: CAUBEL, Patrick, Michel; (US).
FRIEDMAN, Andrew, Joseph; (US)
Agent: JOHNSON, Philip, S.; Johnson & Johnson, One Johnson & Johnson Plaza, New Brunswick, NJ 08933 (US)
Priority Data:
60/363,191 11.03.2002 US
60/381,584 17.05.2002 US
Title (EN) SULFATASE INHIBITING PROGESTOGEN-ONLY CONTRACEPTIVE REGIMENS
(FR) SCHEMAS POSOLOGIQUES CONTRACEPTIFS UNIQUEMENT A BASE DE PROGESTOGENE INHIBANT L'ACTIVITE SULFATASE
Abstract: front page image
(EN)A method of contraception is disclosed comprising the step of administering to a menstruating female a cycle of contraceptive therapy, said cycle of therapy including the continuous administration for the length of the cycle of a potent sulfatase inhibiting progestogen in a contraceptively effective and breast protecting dose, in the absence of the administration of an estrogen.
(FR)La présente invention concerne une méthode de contraception qui comprend une étape d'administration d'un cycle de thérapie contraceptive à une femme menstruée, ledit cycle de thérapie comprenant l'administration continue sur la longueur du cycle d'un puissant progestogène inhibant la sulfatase, avec une dose protégeant les seins des carcinomes et efficace du point de vue contraceptif, en l'absence de l'administration d'un oestrogène.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)